我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

虞坚尔教授辨治小儿重度胆汁淤积性黄疸经验*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2019年06期
页码:
39-44
栏目:
临床研究
出版日期:
2020-06-15

文章信息/Info

Title:
Professor Yu Jianer's Experience of Distinguishing and Treating Severe Cholestatic Jaundice in Children
文章编号:
1000-2723(2019)06-0039-06
作者:
蒋沈华白 莉李利清朴 香武明云虞坚尔△
(上海中医药大学附属市中医医院,上海市中医药研究院中医儿科研究所,上海 200071)
Author(s):
JIANG Shenhua BAI Li LI Liqing PIAO Xiang WU Mingyun YU Jianer
(Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Pediatric Institute of Shanghai Traditional Chinese Medicine Academy,shanghai,200071)
关键词:
重度胆汁淤积性黄疸调脾疏肝扶正固本中西医结合
Keywords:
severe cholestatic jaundice invigorating the spleen and soothing the liver supporting healthy energy combination of traditional Chinese and Western medicine
分类号:
R272
DOI:
10.19288/j.cnki.issn.1000-2723.2019.06.007
文献标识码:
A
摘要:
虞坚尔教授应用中医药治疗小儿疾病积累了丰富的临床经验。在小儿难治性疾病中,特别是重度胆汁淤积性黄疸,虞教授提倡中西医结合,西医治标,中医治本,标本兼顾,各取所长。在中医治疗方面,虞教授专注于“利胆退黄、调脾疏肝、活血祛瘀、扶正固本”四个方面,辨病与辨证相结合,扶正与祛邪并举,正气复而黄自去。
Abstract:
Professor yu jianer is the instructor of the inheritance studio of the fifth and sixth groups of famous Chinese medicine experts in China.He is a famous Chinese medicine doctor in Shanghai. He has been practicing Chinese medicine for more than 40 years and accumulated rich clinical experience in the treatment of pediatric diseases with Chinese medicine. In children refractory diseases, especially severe cholestatic jaundice, professor yu advocated the combined treatment of traditional Chinese and western medicine. Western medicine provide temporary solutions to the problems, while Chinese medicine hit the effect of a permanent cure. Taking care of both tip and root is to take their own advantages. In the treatment of traditional Chinese medicine, professor yu focused on the four aspects of “normalizing gallbladder to cure jaundice, invigorating the spleen and soothing the liver, activating blood circulation and removing blood stasis, supporting healthy energy”. Professor yu combined disease differentiation with syndrome differentiation, strengthened and dispelled evils simultaneously and recovered the positive Qi and stopped the disease.

参考文献/References

[1] FISCHLER B,LAMIREAU T. Cholestasis in the newborn and infant[J]. Clin Res Hepatol Gas,2014,38(3):263-267.
[2] 陈成伟,成军,窦晓光,等. 胆汁淤积性肝病诊断和治疗共识(2015)[J]. 临床肝胆病杂志,2015,31(12):1989-1999.
[3] SHAH R,JOHN S. Cholestatic jaundice(Cholestasis,Cholestatic Hepatitis)[M]. StatPearls [Internet]. StatPearls Publishing,2018.
[4] 周建利,周少明,程勇卫,等. 婴儿胆汁淤积性黄疸的病因、临床特点及转归分析[J]. 实用医学杂志,2016,32(13):2172-2174.
[5] PANEBIANCO C,OBEN J A,VINCIGUERRA M,et al. Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal:a putative synergy between retinoic acid and PPAR-gamma signalings[J]. Clin Exp Med,2017,17(3):269-280.
[6] ASSIS D N,ABDELGHANY O,CAI S Y,et al. Combination therapy of all-trans retinoic acid with ursodeoxycholic acid in patients with primary sclerosing cholangitis:a human pilot study[J]. J Clin Gastroenterol,2017,51(2):e11-e16.
[7] TRAUNER M,FUCHS C D,HALILBASIC E,et al. New therapeutic concepts in bile acid transport and signaling for management of cholestasis[J]. Hepatology,2017,65(4):1393-1404.
[8] KOWDLEY K V,LUKETIC V,CHAPMAN R,et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J]. Hepatology,2018,67(5):1890-1902.
[9] DE VRIES E,BEUERS U. Management of cholestatic disease in 2017[J]. Liver Int,2017(S1):123-129.
[10] FLOREANI A,MANGINI C. Primary biliary cholangitis:old and novel therapy[J]. Eur J Intern Med,2018,47:1-5.
[11] DYSON J K,HIRSCHFIELD G M,ADAMS D H,et al. Novel therapeutic targets in primary biliary cirrhosis[J]. Nat Rev Gastroenterol Hepatol,2015,12(3):147-158.
[12] BEUERS U,TRAUNER M,JANSEN P,et al. New paradigms in the treatment of hepatic cholestasis:from UDCA to FXR,PXR and beyond[J]. Journal of hepatology,2015,62(Suppl. 1):S25-S37.
[13] FANG H,ZHANG A,YU J,et al. Insight into the metabolic mechanism of scoparone on biomarkers for inhibiting Yanghuang syndrome[J]. Sci Rep,2016,6:37519.
[14] 李慧娟,杜成林,王晓静. 垂盆草的研究进展[J]. 药学研究,2015,34(11):661-663.
[15] 龙安予,郑俊霞,刘蕊. 垂盆草苷对实验性幼年大鼠肝内胆汁淤积的干预作用[J]. 辽宁医学杂志,2018,32(2):23-25.
[16] YAN J,XIE G,LIANG C,et al. Herbal medicine Yinchenhaotang protects against α-naphthylisothiocyanate-induced cholestasis in rats[J]. Sci Rep,2017,7(1):4211.
[17] 窦志华,罗琳,孟萍,等. 茵陈蒿汤不同方剂配伍对黄疸模型大鼠肝功能的影响比较[J]. 南通大学学报(医学版),2017,37(1):17-20.
[18] 蔡小蓉,杨建云,肖炳坤,等. 茵陈五苓散对α-萘异硫氰酸酯致大鼠黄疸型肝损伤的血清代谢组学研究[J]. 中国临床药理学杂志,2018,34(7):848-851.
[19] ZENG J,WANG S J,LI Y M,et al. Yinzhihuang oral liquid in the treatment of neonatal jaundice:a meta-analysis[J]. Pharm Biol,2017,55(1):554-559.
[20] 谢辉,谢艳,张若蒙,等. 茵栀黄口服液对新生儿黄疸特征标记物影响的研究分析[J]. 吉林医学,2017,38(6):1052-1054.
[21] 苏峰,郝少君,孙建华,等. 复方黄栌口服液对小鼠黄疸型肝炎模型血清中指标的影响[J]. 实用药物与临床,2016,19(11):1325-1328.
[22] 苏峰,郝少君,黎丹东,等. 复方黄栌口服液对小鼠黄疸型肝炎模型肝脏中指标的影响[J]. 中华中医药学刊,2017,35(8):2176-2178.

备注/Memo

备注/Memo:
收稿日期: 2019 - 11- 26
* 基金项目: :国家自然科学基金青年项目(81603662);上海市科委青年科技英才扬帆计划资助(16YF1410800)
第一作者简介: 蒋沈华(1990-),女,在读博士研究生,研究方向:小儿肺、脾、肾系疾病。
△通信作者: 虞坚尔,E-mail: jianeryu@hotmial.com
更新日期/Last Update: 2020-06-30